Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Precision BioSciences, Inc.NASDAQ: DTIL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $640K fell 9.2% year over year, ahead of the -30.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -32.6% a year.

Context

  • Depreciation & amortization amounted to 8.0% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -9.2% holds above the trailing-twelve-month pace of -30.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$640K-5.6% QoQ
Last fiscal yearDec 2025
$2.75M-39.9% YoY
LTMMar 2026
$2.69M-30.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.2%——
1 year-39.9%——
3-year CAGR-32.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.75M USD
Year-over-year change
-39.9%
4-year CAGR
-27.9%

Depreciation & Amortization vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's LTM Mar 2026 depreciation & amortization of $2.69M is the 2nd largest of the 7 companies compared; the peer median is $886K.
  • Its year-over-year change of -30.3% is the 4th highest of 6, against a peer median of -16.1%.
  • Depreciation & amortization amounts to 6.0% of revenue for DTIL, versus a peer median of 1.6%.
DTIL Competitors Peer median
Depreciation & Amortization for DTIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$8.78M +4.6%—47.7%
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M -30.3%-32.6%6.0%
HRTXHeron Therapeutics, Inc.LTM Mar 2026$2.29M -16.1%-7.1%1.5%
GOSSGossamer Bio, Inc.LTM Mar 2026$892K -74.4%-39.1%1.6%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$880K +391.6%——
RNAAtrium Therapeutics, Inc.FY2025$323K ——1.7%
QTTBQ32 Bio Inc.LTM Mar 2026$305K -36.9%+1.9%0.6%
Peer median (excluding DTIL) $886K-16.1%-7.1%1.6%

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.6M)(111.64M)(61.32M)7.17M(45.72M)
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
Deferred Income Tax00000
Stock-Based Compensation16.51M19.2M14.04M12.6M10.19M
Change in Working Capital19.58M24.11M(41.49M)(54M)(24.71M)
Accounts Receivables9.51M(232K)(181K)10.42M229K
Inventory00000
Accounts Payables867K153K1.51M(2.1M)(737K)
Other Working Capital9.21M24.19M(42.81M)(62.33M)(24.2M)
Other Non-Cash Items(26.55M)13.57M(3.6M)(28.79M)(8.35M)
Operating Cash Flow(10.85M)(45.75M)(84.11M)(58.45M)(65.84M)
Capital Expenditures(5.8M)(3.32M)(2.28M)(250K)(85K)
Acquisitions (Net)008M60K0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(750K)0107K(25K)(549K)
Investing Cash Flow(5.8M)(3.32M)5.83M(215K)(634K)
Debt Repayment2.47M19.81M0(37K)0
Common Stock Issued60.48M74.35M4.99M50.24M95.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.57M835K401K249K0
Financing Cash Flow70.52M94.99M5.39M50.45M95.16M
Effect of Forex Changes00000
Net Change in Cash53.87M45.91M(72.9M)(8.21M)28.69M
Free Cash Flow(16.66M)(49.07M)(86.39M)(58.7M)(65.93M)

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.